Application | Comment | Organism |
---|---|---|
medicine | MGMT significantly protects against in vivo temozolomide-induced mutations | Mus musculus |
Protein Variants | Comment | Organism |
---|---|---|
additional information | MGMT deficiency does not result in greater mutation frequency following cyclophosphamide or 1,3-bis (2-chloroethyl)-1-nitrosourea compared with wild-type mice | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
O6-benzylguanine | pretreatment of Mgmt+/+ mice prior to 1,3-bis (2-chloroethyl)-1-nitrosourea does not result in significantly more mutations than mice treated with 1,3-bis (2-chloroethyl)-1-nitrosourea alone | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
C57BL/6 and F1 (C57BL/6 x 129/Sv) wild-type mice | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
spleen | - |
Mus musculus | - |
T-lymphocyte | - |
Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
MGMT | - |
Mus musculus |
O6-methylguanine-DNA methyltransferase | - |
Mus musculus |